Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 Myeloma Highlights
04 February 2025 | Virtual Webinar
Post-ASH 2024 Myeloma Highlights
Featuring presentations & discussions on selected myeloma abstracts from the 66th ASH Annual Meeting and Exposition
Tuesday 4 February | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00 – 19:00 CET
Chair: Marc Raab | Moderators: Yi Lin and Elena Zamagni
The Post-ASH 2024 Myeloma Highlights was supported by Johnson & Johnson. Supporters have no influence over the production of content.
Explore all presentations and discussions below:
Session 1: Novel treatments and treatment combinations in the frontline setting
Belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
Isatuximab, lenalidomide, bortezomib and dexamethasone induction therapy for transplant-eligible patients with newly diagnosed multiple myeloma
Elias Mai Heidelberg University, Heidelberg, Baden-Württemberg, Germany
Teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM)
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
Safety run-in (SRI) results from the Majestec-4/EMN30 trial
Elena Zamagni University of Bologna, Bologna, Italy
Panel discussion
Session 2: Latest evidence with bispecifics, CELMoDs, and CAR T-cell therapy in the R/R setting
Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM)
Joshua Richter Mount Sinai Medical Center, NY, United States
Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM)
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
Talquetamab bridging: Paving the way to B-cell maturation antigen (BCMA) CAR T-cell therapy in relapsed/refractory multiple myeloma (RRMM)
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy, in patients (pts) with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM)
Susan Bal University of Alabama, Birmingham, AL, United States
Anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma
Ciara Freeman Moffitt Cancer Center, Tampa, FL, United States
Panel discussion
Session 3: Updates in the management of frail patients, smoldering multiple myeloma and amyloidosis
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
Early safety and efficacy of CAR T-cell therapy in precursor myeloma
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States
Subcutaneousd Daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis
Efstathios Kastritis National and Kapodistrian University of Athens, Athens, Greece
Panel discussion
